7 stories mentioning JANX
Every FINWIRES story that references JANX, newest first.
Janux Therapeutics (JANX) has an average rating of Buy and mean price target of $27.20, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $14.19, Change: $-0.35, Percent Change: -2.41%
Janux Therapeutics (JANX) has an average rating of overweight and mean price target of $45.81, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Health care stocks were lower late Wednesday afternoon, with the NYSE Health Care Index down 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.7%.The iShares Biotechnology ETF (IBB) was fractionally higher.In corporate news, GSK (GSK) said Wednesday it has completed its $950 million acquisition of 35Pharma, adding an experimental pulmonary hypertension therapy to its respiratory, immunology and inflammation pipeline. GSK shares were down 2.1%.Janux Therapeutics (JANX) lacks near-term stock-moving catalysts after it came under pressure following mixed results from the phase 1a trial of JANX007 in 5L metastatic prostate cancer, UBS said in a report. UBS downgraded the stock to neutral from buy and cut its price target to $15 from $57. Janux shares fell 1.1%.GoodRx (GDRX) shares climbed up 4.3% after the firm said Wednesday it is offering Novo Nordisk's (NVO) Wegovy HD 7.2 mg injectable weight loss drug to eligible self-pay patients. Novo shares rose 3.7%.Immutep (IMMP) shares surged 73% after it said the US Food and Drug Administration has granted orphan drug designation to eftilagimod alfa to treat soft tissue sarcoma, a rare cancer.
Health care stocks were lower Wednesday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding about 0.9%.The iShares Biotechnology ETF (IBB) decreased 0.4%.In corporate news, Janux Therapeutics (JANX) lacks near-term stock-moving catalysts after it came under pressure following mixed results from the phase 1a trial of JANX007 in 5L metastatic prostate cancer, UBS said in a report. UBS downgraded the stock to neutral from buy and cut its price target to $15 from $57. Janux shares fell 2.9%.GoodRx (GDRX) shares climbed up 3.8% after the firm said Wednesday it is offering Novo Nordisk's (NVO) Wegovy HD 7.2 mg injectable weight loss drug to eligible self-pay patients. Novo shares rose 2.2%.Immutep (IMMP) shares doubled after the firm said the US Food and Drug Administration has granted orphan drug designation to eftilagimod alfa to treat soft tissue sarcoma, a rare cancer.
Health care stocks declined Wednesday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding 0.9%.The iShares Biotechnology ETF (IBB) decreased 0.4%.In corporate news, Janux Therapeutics (JANX) lacks near-term stock-moving catalysts after it came under pressure following mixed results from the phase 1a trial of JANX007 in 5L metastatic prostate cancer, UBS said in a report. UBS downgraded the stock to neutral from buy and lowered its price target to $15 from $57. Janux shares were down 3%.
Janux Therapeutics (JANX) lacks near-term stock-moving catalysts after the stock came under pressure following mixed results from phase 1a trial of JANX007 in 5L metastatic prostate cancer, UBS said in a Wednesday report.The report said focus will now be on the phase 1b update in taxane-naive metastatic castration-resistant prostate cancer population in H2, with upside depending on whether the data showing a clean safety profile and durable radiographic progression-free survival compared with Pluvicto."We think 2H26 data will likely be incremental with limited impact on the stock," the note said, given among others that that the trial is in dose optimization.The report said a more substantial update may be in 2027, whenmore patients from expansion cohorts and more mature follow-up are expected.UBS downgraded the stock to neutral from buy and lowered its price target to $15 from $57.Price: $14.77, Change: $-0.47, Percent Change: -3.08%
Janux Therapeutics (JANX) has an average rating of Buy and mean price target of $46.75, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)